ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2049

ILD Associated with Primary Sjögren’s Syndrome Is Frequently Progressive

Anna-Maria Hoffmann-Vold1, Håvard Fretheim1, Phoung Phoung Diep1, Karoline Lerang2, Birgir Gudbransson1, Helena Andersson1, Øyvind Midtvedt1, Torhild Garen1, Michael Durheim1, Trond Mogens Aaløkken1, Øyvind Palm1 and Øyvind Molberg2, 1Oslo University Hospital, Oslo, Norway, 2Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway

Meeting: ACR Convergence 2022

Keywords: Cohort Study, interstitial lung disease, prognostic factors, Sjögren's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: Sjögren's Syndrome – Basic and Clinical Science Poster

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Interstitial lung disease (ILD) in primary Sjögren’s syndrome (pSS) has been reported to be present in 10-15% of patients, but ILD progression in pSS-ILD has not been assessed in detail. The objective of this study was to assess ILD progression in pSS and factors associated with disease progression in a well-characterized pSS-ILD cohort.

Methods: All pSS patients with ILD diagnosed on HRCT from the Oslo University Hospital (OUH) were included. Clinical characteristics, treatment (including rituximab, other immunosuppressives, hydroxychloroquine, nintedanib and lung transplantation), lung function tests including forced vital capacity (FVC) and diffusing capacity for carbon monoxide (DLCO), and ILD pattern on HRCT assessed by a radiologist were evaluated. We determined ILD progression defined as (1) absolute FVC decline >5%; or (2) absolute DLCO decline >10% over 12 +/-6 months; or (3) increasing extent of ILD on HRCT over the observation period. Potential risk factors associated with disease progression were chosen based on expert opinion. Descriptive analyses were conducted.

Results: Of 702 pSS patients followed at OUH, we identified 60 pSS patients with ILD with 33 (55%) having followup at 12 months (Table). Mean time from pSS to ILD diagnosis was 7.4 years. In 67% ILD was diagnosed after pSS, in 13% simultaneously, and in 11% before pSS diagnosis. In total, 28 (47%) had lymphocytic interstitial pneumonia (LIP) and 32 (53%) reticular pattern on HRCT. Of all, 33 (53%) were treated (Table). Over mean followup of 10.9 months (SD 4.2), 7/33 (21%) showed FVC >5% decline, 9/32 (28%) DLCO >10% decline and 12 (36%) had at least one of these defined lung function declines on standard of care treatment (Figure 1). Over an observation period of 15.4 (SD 10.6) years, 27/47 (45%) showed any ILD progression on HRCT (Figure 1). HRCT pattern was not associated with risk of >10% DLCO decline or ILD progression on HCRT. >5% FVC decline occurred more frequently in patients with reticular pattern compared to LIP (6/17 (35%) vs 1/16 (6%), p=0.041). Factors significantly associated with ILD progression on lung function (either FVC eller DLCO decline) included higher baseline FVC (99% (SD16.4) vs 87% (SD14.9), p=0.032), higher DLCO (81% (SD13.1) vs 67% (SD17.4), p=0.020), increased CRP (2/10 (20%) vs 0/16 (0%), p=0.045), presence of polyneuropathy (2/9 (22%) vs 1/17 (6%), p=0.045) and numerically male sex (2/12 (25%) vs 1/21 (6%), p=0.087) (Figure 2). Treatment was not associated with ILD progression.

Conclusion: A substantial number of patients with pSS-ILD progressed on standard of care treatment. This highlights the importance of close monitoring and active consideration of treatment initiation and escalation in pSS-ILD.

Supporting image 1

Table1: Clinical characteristics, demographics and outcome of pSS with ILD

Supporting image 2

Figure 1: ILD progression in pSS

Supporting image 3

Figure 2: Baseline characteristics significantly associated with ILD progression in pSS-ILD


Disclosures: A. Hoffmann-Vold, Boehringer-Ingelheim, Janssen, Eli Lilly, Merck/MSD, Roche; H. Fretheim, Bayer, GSK and Actelion; P. Diep, Boehringer Ingelheim; K. Lerang, None; B. Gudbransson, None; H. Andersson, Boehringer Ingelheim; Ø. Midtvedt, Jannsen, Boehringer-Ingelheim; T. Garen, None; M. Durheim, Boehringer Ingelheim, Roche; T. Aaløkken, Boehringer Ingelheim; Ø. Palm, None; Ø. Molberg, None.

To cite this abstract in AMA style:

Hoffmann-Vold A, Fretheim H, Diep P, Lerang K, Gudbransson B, Andersson H, Midtvedt Ø, Garen T, Durheim M, Aaløkken T, Palm Ø, Molberg Ø. ILD Associated with Primary Sjögren’s Syndrome Is Frequently Progressive [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/ild-associated-with-primary-sjogrens-syndrome-is-frequently-progressive/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/ild-associated-with-primary-sjogrens-syndrome-is-frequently-progressive/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology